cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ionis Pharmaceuticals Inc
6 own
25 watching
Current Price
$0
$-0.21
(-0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
6,141.39M
52-Week High
52-Week High
48.82
52-Week Low
52-Week Low
32.69
Average Volume
Average Volume
0.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
106.6829
iconMarket Capitalization6,141.39M
icon52-Week High48.82
icon52-Week Low32.69
iconAverage Volume0.12M
iconDividend Yield--
iconP/E Ratio106.6829
What does the Ionis Pharmaceuticals Inc do?
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company's flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with...
Read More
How much money does Ionis Pharmaceuticals Inc make?
News & Events about Ionis Pharmaceuticals Inc.
Zolmax
1month ago
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS Get Rating) Analysts at SVB Leerink raised their FY2024 earnings per share estimates for shares of Ionis Pharmaceuticals in a report issued on Tuesday, April 25th. SVB Leerink analyst M. Foroohar now expects that the company will post earnings of ($3.93) per ...
PR Newswire
2 months ago
New data presented at AD/PD2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease New data presented at AD/PD2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease PR Newswire...
PR Newswire
2 months ago
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN PR Newswire CARLSBAD, Calif., March 27, 2023 Eplontersen met co-primary endpoints...
PR Newswire
2 months ago
Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS PR Newswire CARLSBAD, Calif., March 22, 2023 If approved...
Frequently Asked Questions
Frequently Asked Questions
What is Ionis Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Ionis Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Ionis Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Ionis Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ionis Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Ionis Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Ionis Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ionis Pharmaceuticals Inc?
plus_minus_icon
What percentage is Ionis Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ionis Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.21
(-0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$25.91
$0.20 (0.76 %)
Catalent, Inc.
Catalent, Inc.
$36.81
$0.00 (0.00 %)
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
$50.55
$0.94 (1.88 %)
United Therapeutics Corporation
United Therapeutics Corporation
$213.85
$0.37 (0.17 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$25.91
$0.20 (0.76 %)
Catalent, Inc.
Catalent, Inc.
$36.81
$0.00 (0.00 %)
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
$50.55
$0.94 (1.88 %)
United Therapeutics Corporation
United Therapeutics Corporation
$213.85
$0.37 (0.17 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00